or by other unknown mechanisms. Resistance to imatinib frequently develops in patients with advanced disease. In this setting, resistance develops within few months of treatment and imatinib dose increase has a rather limited impact.
Patients who achieve a complete cytogenetic remission (CCR) and maintain it for an extended period of time (46 months) represent a completely different population. In this group of patients, responses are quite durable (Silver et al. Blood 2004; 104: 23, abstract), and the achievement of a CCR represents one of the major prognostic factors, 3 together with the extent of reduction of the BCR-ABL transcript. 4 However, even in these patients, the progression-free survival curve does not seem to be reaching a plateau (Kantarjian et We present here the experience at our center with four chronic myeloid leukemia (CML) patients who achieved a durable CCR, developed a cytogenetic relapse and underwent a second CCR after a dose-increase of imatinib (up to 1200 mg in two cases).
These patients are a subset of the patients in either chronic or accelerated phase (AP) who entered five different registrative or nonregistrative protocols of imatinib monotherapy at a single center between 1999 and 2001.
The initial dose of imatinib was 400 mg daily. Cytogenetic analysis was performed on bone marrow aspirates every 3 months (first year) and every 6 months (subsequently). CCR was defined as the absence of Ph þ metaphases in at least 20 examined cells; CCR was considered durable when it lasted for at least 6 months.
Patients were dose-increased to 800 mg daily if complete hematological response (CHR) was not achieved at 3 months, if a CCR was not achieved after a 1-year treatment or in presence of relapse. A further increase to 1200 mg daily was performed in patients who relapsed at 800 mg.
Patients were considered in relapse when a transformation to AP or blast crisis (BC) occurred or when a loss of hematological or cytogenetic response developed (confirmed after 4 weeks).
The characteristics of these four patients are presented in Table 1 .
Patient 11 started imatinib (400 mg daily) in April 2000 and he underwent a dose-increase to 800 mg after 3 months for lack of CHR. He obtained the CCR 14 months after the dose increase. CCR was lost in October 2002, with cytogenetic analysis indicating the presence of 45% Ph þ metaphases. Neither amplification of the fusion region nor point mutations in the kinase domain of BCR-ABL or in the SH2, SH3 and SH2-3 connector domains were found. Imatinib dosage was then further increased to 1200 mg daily with no severe toxicity and a new CCR was obtained after 3 months. Patient 11 is still on treatment with imatinib at 1200 mg daily.
Patient 13 started imatinib at 400 mg, obtaining a CCR after 6 months of therapy. After 31 months of therapy, cytogenetic analysis showed the presence of 10% Ph þ metaphases. Neither amplification nor point mutations of BCR-ABL were found. Imatinib dosage was then increased to 600 mg daily (the standard dose increase to 800 mg daily was lowered to 600 mg because the patient refused an higher dose) and a new CCR was achieved after 7 months from the dose-increase. Patient 13 is currently treated with 600 mg daily dosage with no sign of relapse or progression.
Patient 27 started imatinib (400 mg daily) in January 2000. After 9 months he obtained a CCR that lasted 14 months. In December 2001, cytogenetic analysis showed the presence of 20% Ph þ metaphases. FISH analysis performed on the same sample showed the presence of an isoderivative chromosome 22 (idic(22)(9q34;9q34)t(9;22)(q34;q11.2) ish der(22)(BCR/ABL þ þ þ þ )). FISH analysis showed that the fusion region was amplified in this chromosome, generating an intense fluorescence signal (Figure 1 ). The fluorescence in the derivative chromosome was found to be 4.5 times higher than in the individual fusion (assessed on the preimatinib sample). No mutations of BCR-ABL were detected. The dose of the drug was increased to 800 mg daily, obtaining a second CCR after 3 months. Patient 27 is currently in CCR.
Patient 32 was diagnosed for CP-CML in March 1995. In January 2000, imatinib, 400 mg daily, was started. After 12 months he obtained only a minor cytogenetic response, thus he was dose-increased to 800 mg daily. After 6 months from the dose-increase he achieved CCR. Clonal mutational screening on a BM sample taken 3 months after the achievement of CCR revealed the presence of mutation F359V on 6/10 clones analyzed. No amplification of the fusion region was present. He remained on CCR for 16 months, then, in November 2002, cytogenetic analysis showed 35% of Ph þ metaphases. He was then dose increased to 1200 mg daily and, after 3 months, he achieved a new CCR, which lasted 6 months. Clonal mutational screening on a BM sample taken 3 months after the dose increase revealed however further selection and progression, with mutation F359V being present in 10/10 clones. A second mutation, D276G, was identified in 2/10 clones.
In all four cases reported here, the relapse developed at cytogenetic level (loss of CCR, confirmed at 4 weeks), with normal peripheral blood values and without progression to BC or AP.
All the four patients received an increase in the imatinib dose. Three of them achieved a second CCR within 3 months after the dose increase and three are still in CCR (duration: þ 19, þ 9, þ 31 months). Even in the fourth case, the CCR obtained allow the patient to 'buy time' and be able to start treatment with a new ABL inhibitor.
Although three out of four patients achieved durable second remissions, the small number of this group does not allow definitive conclusions on the durability of these responses.
Side effects were similar to those observed at lower dosage. Interestingly, patients 11 and 32 were treated with 1200 mg imatinib daily for 20 and 19 months, respectively, with no severe toxicity (patient 11 developed gynecomastia).
These data indicate that, in presence of relapse, it is possible to achieve a second CCR by an increment in the dosage of the drug. Two patients who underwent relapse during treatment with imatinib 400 mg daily obtained a second CCR after a dose increase to 600 and 800 mg daily. In addition, two patients who suffered relapse during treatment at 800 mg were treated with 1200 mg daily, and in both cases a new CCR was obtained.
Previous reports showed that imatinib at 800 mg/day can lead to higher rates of complete cytogenetic and molecular responses compared to 400 mg/day in CML patients, 5 and that a dose increase up to 800 mg in relapsed CML patients can lead to new cytogenetic remissions (either complete or partial), 6 even if sometimes short-lived. 7, 8 Moreover, in a phase I study, 9 doses up to 1000 mg were used, with no dose-limiting toxicity.
To our knowledge, this represents the first report on the clinical usage of imatinib at 1200 mg, especially in CML patients relapsing after a durable CCR.
These findings indicate that a daily dose of 800 mg is not an absolute limit in the treatment of CML, and that an increase in the dosage of imatinib to at least 800 mg daily, if tolerable, should be tried before defining a patient as resistant to imatinib.
Even if the achievement of a second CCR in all the four patients that relapsed and a durable CCR in three of them sounds encouraging, prudence is required. First, none of the patients in this cohort became PCR-negative, neither in first nor in second remission. Second, clonal mutational screening on patient 32 shows that, after the dose increase, 100% of the clones became positive for mutation F359V, with a second mutation, D276G, present in 2/10 clones, while the patient was in CCR. Notably, mutations F359V and D276G decrease the sensitivity to imatinib via two different mechanisms. 1, 10, 11 This could potentially lead, in our opinion, to an additive effect between F359V and D276G in the clones in which both mutations are present. It will be interesting to further analyze the dynamic evolution of the mutant clones in this patient, who at present is being treated with dasatinib (formerly BMS-354825).
Finally, patients with clonal evolution, such as patients 27 and 32, show that even in the presence of CCR, selection of clones continues. The detection of BCR-ABL mutations was particularly negative, since the only patient who presented it, was also the only one who lost his second CCR.
These data indicate, in our opinion, that it is important to characterize the molecular mechanisms of resistance to imatinib and the corresponding decrease in sensitivity to the drug in relapsed patients, in order to develop treatment schemes targeted on the single patient.
In conclusion, imatinib dose increase up to 1200 mg/day was well tolerated and effective in this population, although new ABL inhibitors (AMN 107, dasatinib, SKI 606), already in clinical trials, should be considered, especially for patients presenting BCR-ABL mutations. The data contained here could result useful to physicians treating CML. FISH analysis on patient 27. FISH analysis using the LSI BCR-ABL ES double fluorescent probe on a BM sample from patient 27 obtained during relapse shows the presence of BCR-ABL amplification (red arrow; BCR is identified by a green probe; ABL by a red probe). BCR and ABL unrearranged genes are shown as single green and red spots, respectively (green arrows). Quantitative analysis indicates a 4.5-fold increase in the intensity of the fusion gene compared with BCR and ABL alone. 
